🚀 VC round data is live in beta, check it out!
SoftOx Solutions Valuation Multiples
Discover revenue and EBITDA valuation multiples for SoftOx Solutions and similar public comparables like Tevogen Bio, Molecure, Tvardi Therapeutics, BioXcel Therapeutics and more.
SoftOx Solutions Overview
About SoftOx Solutions
SoftOx Solutions AS is a clinical-stage pharmaceutical company. The company offers antimicrobial solutions for Wound and Skin Care. It has developed an effective antimicrobial solution to combat biofilm, viral, and antimicrobial-resistant infections. The technology is based on extensive research and development in partnership with Nordic research institutes.
Founded
2012
HQ
Employees
5
Website
Sectors
Financials (FY)
EV
$28M
SoftOx Solutions Financials
SoftOx Solutions reported last fiscal year revenue of $2M and negative EBITDA of ($875K).
In the same fiscal year, SoftOx Solutions generated ($875K) in EBITDA losses and had net loss of ($1M).
SoftOx Solutions P&L
In the most recent fiscal year, SoftOx Solutions reported revenue of $2M and EBITDA of ($875K).
SoftOx Solutions expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $2M | XXX | XXX | XXX |
| EBITDA | — | XXX | ($875K) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (52%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (73%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($1M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (69%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
SoftOx Solutions Stock Performance
SoftOx Solutions has current market cap of $31M, and enterprise value of $28M.
Market Cap Evolution
SoftOx Solutions' stock price is $0.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $28M | $31M | -4.4% | XXX | XXX | XXX | $-0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSoftOx Solutions Valuation Multiples
SoftOx Solutions trades at 17.0x EV/Revenue multiple, and (32.5x) EV/EBITDA.
SoftOx Solutions Financial Valuation Multiples
As of April 18, 2026, SoftOx Solutions has market cap of $31M and EV of $28M.
Equity research analysts estimate SoftOx Solutions' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
SoftOx Solutions has a P/E ratio of (26.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $31M | XXX | $31M | XXX | XXX | XXX |
| EV (current) | $28M | XXX | $28M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 17.0x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (32.5x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (23.4x) | XXX | XXX | XXX |
| P/E | — | XXX | (26.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (14.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified SoftOx Solutions Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
SoftOx Solutions Margins & Growth Rates
SoftOx Solutions' revenue in the last fiscal year grew by —.
SoftOx Solutions' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.6M for the same period.
SoftOx Solutions Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Margin | — | XXX | (52%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (77%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 173% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
SoftOx Solutions Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| SoftOx Solutions | XXX | XXX | XXX | XXX | XXX | XXX |
| Tevogen Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| Molecure | XXX | XXX | XXX | XXX | XXX | XXX |
| Tvardi Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| BioXcel Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Lisata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SoftOx Solutions M&A Activity
SoftOx Solutions acquired XXX companies to date.
Last acquisition by SoftOx Solutions was on XXXXXXXX, XXXXX. SoftOx Solutions acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by SoftOx Solutions
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSoftOx Solutions Investment Activity
SoftOx Solutions invested in XXX companies to date.
SoftOx Solutions made its latest investment on XXXXXXXX, XXXXX. SoftOx Solutions invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by SoftOx Solutions
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout SoftOx Solutions
| When was SoftOx Solutions founded? | SoftOx Solutions was founded in 2012. |
| Where is SoftOx Solutions headquartered? | SoftOx Solutions is headquartered in Norway. |
| How many employees does SoftOx Solutions have? | As of today, SoftOx Solutions has over 5 employees. |
| Is SoftOx Solutions publicly listed? | Yes, SoftOx Solutions is a public company listed on Oslo Børs. |
| What is the stock symbol of SoftOx Solutions? | SoftOx Solutions trades under SOFTX ticker. |
| When did SoftOx Solutions go public? | SoftOx Solutions went public in 2018. |
| Who are competitors of SoftOx Solutions? | SoftOx Solutions main competitors are Tevogen Bio, Molecure, Tvardi Therapeutics, BioXcel Therapeutics. |
| What is the current market cap of SoftOx Solutions? | SoftOx Solutions' current market cap is $31M. |
| What is the current revenue of SoftOx Solutions? | SoftOx Solutions' last fiscal year revenue is $2M. |
| What is the current EV/Revenue multiple of SoftOx Solutions? | Current revenue multiple of SoftOx Solutions is 17.0x. |
| Is SoftOx Solutions profitable? | No, SoftOx Solutions is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.